Biotech Values

[walldiver]

I should credit David Miller for the idea behind the paragraph, that the shorts will change their tune each time more data is released. He has been spot on. I've just added a few examples. My favorite is UBS analyst Maged Shenouda, AKA "Magoo," believing that soft tissue metastases are more indicative of end-stage PC than bony metastases. When he brought up that argument on the 2/22 conference call, DNDN's CSO could barely conceal the contempt in his answer.